Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481249 | 0.91 | PTGER4 (0.33) | PTGER4CYSLTR1CYSLTR2TBXAS1GRM2 | |
| SCHEMBL481104 | 0.80 | PTGER4 (0.34) | PTGER4CREBBPEP300 | |
| SCHEMBL481296 | 0.78 | CYSLTR1 (0.42) | CYSLTR1CYSLTR2TBXAS1GRM2LTB4R | |
| SCHEMBL1755751 | 0.78 | PTGER4 (0.35) | PTGER4CYSLTR1CYSLTR2TBXAS1LTB4R | |
| SCHEMBL481142 | 0.77 | CYSLTR1 (0.42) | CYSLTR1CYSLTR2TBXAS1GRM2LTB4R | |
| SCHEMBL481242 | 0.76 | CCR5 (0.32) | PTGER4CYSLTR1CYSLTR2TBXAS1GRM2 | |
| SCHEMBL480877 | 0.76 | PPARG (0.34) | PTGER4CYSLTR1CYSLTR2TBXAS1GRM2 | |
| SCHEMBL480875 | 0.76 | PPARG (0.34) | PTGER4CYSLTR1CYSLTR2TBXAS1GRM2 | |
| SCHEMBL480876 | 0.76 | PPARG (0.34) | PTGER4CYSLTR1CYSLTR2TBXAS1GRM2 | |
| SCHEMBL1755706 | 0.76 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2TBXAS1GRM2LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | PTGER4 572/4885CYSLTR1 85/4885CYSLTR2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.